Zacks Industry Outlook Highlights: The Medicines Company, Optimer Pharma and Cubist Pharma

Zacks

For Immediate Release

 

Chicago, IL – August 10, 2012 – Today, Zacks Equity Research discusses the U.S. Pharma & Biotech, including The Medicines Company (MDCO), Optimer Pharma (OPTR) and Cubist Pharma (CBST).

 

 

A synopsis of today’s Industry Outlook is presented below. The full article can be read at  

http://www.zacks.com/stock/news/80783/pharma-biotech-stock-outlook-aug-2012

 

 

A major event that will have a significant impact pharma and biotech stocks is the upholding of the Patient Protection and Affordable Care Act (:ACA) by the Supreme Court in late June 2012. The Act, popularly referred to as “Obamacare,” passed through Congress in 2010, represents major changes in the nation’s healthcare sector.

The Act will provide coverage to 32 million uninsured Americans, make healthcare facilities more affordable, expand coverage for customers with pre-existing health conditions and keep a check on health insurers. The healthcare reform aims to end the discrimination policy of insurance companies, create competition amongst insurers through the establishment of health insurance exchanges, add value to the overall healthcare system and reduce premiums.

The upholding of the Act is a big win for pharma companies as the coverage base will increase.

Meanwhile, the signing of the Gaining Antiobiotic Incentives Now (GAIN) Act should benefit companies pursuing the development of novel antibiotics. Once approved, these products will enjoy an additional five years of marketing exclusivity. Companies that should benefit from this Act include The Medicines Company (MDCO), Optimer Pharma (OPTR) and Cubist Pharma (CBST) among others.

Another important event in the past few weeks was the signing of the Food and Drug Administration Safety and Innovation Act (:FDASIA) of 2012. This new law includes the reauthorization of the Prescription Drug User Fee Act (:PDUFA), under which the FDA is provided with funds and resources needed to ensure the smooth and timely review of drugs.

 

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

 

 

 

 

About Zacks

 

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

 

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

 

Follow us on Twitter:  http://twitter.com/zacksresearch

 

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

 

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

 

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Read the analyst report on MDCO

Read the analyst report on OPTR

Read the analyst report on CBST

Zacks Investment Research



More From Zacks.com

Rates

View Comments